Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing

 
• By Francesca Bruce

Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.

Multiple Sclerosis
NICE Rejects Ocrevus For MS

More from Europe

More from Geography